Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy

Glen Le Flahec; Manon Briolais; Briac Guibourg; Gilles Lemasson; Jean-Luc Grippari; Francoise Ledé; Pascale Marcorelles; Arnaud Uguen

doi:10.1136/jclinpath-2019-206026

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

75th Anniversary

For authors

About

Call for Papers
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Short report

Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Le Flahec G, Briolais M, Guibourg B, et al

Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy

Journal of Clinical Pathology 2020;73:116-119.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password